For laboratory and research use only. Not for human consumption.
Cartalax 20mg lyophilized vial - US manufactured research peptideCertificate per batchFor laboratory and research use only

The catalog

Cartalax

Tripeptide bioregulator (AED) studied for proposed role in cartilage and bone tissue metabolism. Part of Professor Khavinson’s bioregulator series. US-manufactured. ISO 17025 certificate per batch.

Vial formatISO 17025 certificateHPLC purityMass-spec identity

For laboratory and research use only. Not for human consumption.

SourcingAudited U.S. and E.U. facilities. FDA-registered API trail.
IdentityConfirmed by mass spectrometry per batch.
PurityHPLC measured. Printed on the certificate.

FeelGood does not provide dosing guidance, administration instructions, or protocols. Products are supplied for laboratory and research use only and are not intended for human consumption.

The research

What the published literature examined.

Cartalax is a tripeptide bioregulator studied for its proposed role in cartilage and bone tissue metabolism. It is part of Professor Khavinson’s bioregulator series, with a proposed target in connective tissue.

About the Compound

Cartalax (also referred to as AED) is a synthetic tripeptide with the sequence Alanine-Glutamic acid-Aspartic acid. It is classified as a cytogen in the Khavinson taxonomy, with cartilage and bone as its proposed target tissues, distinguishing it from bioregulators directed at the pineal gland, thymus, or vasculature.

Research on Cartalax has examined its proposed effects on chondrocyte activity, bone mineral density in aging models, and connective tissue repair mechanisms. This makes it of particular interest in musculoskeletal aging research, where cartilage degradation and impaired tissue repair are central physiological problems.

Research Areas

  • Chondrocyte activity. Animal studies have examined effects on cartilage cell proliferation and extracellular matrix production.
  • Bone metabolism. Research has investigated effects on osteoblast and osteoclast activity in aging models, with relevance to bone density research.
  • Connective tissue aging. Khavinson group studies have examined proposed effects on gene expression in cartilage tissue through cytogen-DNA interaction.

The research base is primarily from Khavinson’s group. Independent Western replication is limited. Human clinical data does not exist in published form.

Specifications

  • Compound: Cartalax (AED)
  • Sequence: Ala-Glu-Asp
  • Molecular weight: 317.27 Da
  • Form: Lyophilized powder, sealed glass vial
  • Size: 20mg
  • Purity: ≥98% by HPLC, batch-verified
  • Identity: Mass spectrometry confirmation per batch
  • Endotoxin: LAL assay per batch, reported on COA
  • Storage: −20°C sealed; 4°C after reconstitution, used within 28 days
  • Manufacturing: United States
  • Testing: Independent ISO 17025-accredited laboratory, batch-specific
  • Shipping: Temperature-controlled with insulated packaging

The Standard

Every batch of FeelGood Cartalax is manufactured in the United States and tested by an independent ISO 17025-accredited laboratory before release. The certificate of analysis specific to your lot ships with the order.

Sold as a research chemical for laboratory and research purposes only. Not intended for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.

Findings summarized in neutral terms based on the published literature. Most of the cited research is preclinical. Sold for research use only.